When the Agentic Internet Shows Up to Work: Cloudflare’s Q4 Surprise and a Bullish 2026 Outlook
Cloudflare just reminded the market why infrastructure businesses can suddenly feel like the center of the AI party. On February 10, 2026, the company reported a stronger-than-expected fourth quarter and issued a 2026 revenue outlook that beat consensus — and the stock reacted accordingly. But beneath the headline beats lies a mix of durable growth signals, new AI-driven demand, and a few technical and valuation wrinkles investors should notice.
Quick snapshot you can skim
- Quarter reported on February 10, 2026: revenue $614.5M (up ~34% year-over-year).
- Q4 non-GAAP EPS: $0.28.
- Full-year 2026 revenue guide: $2.79B and adjusted EPS guidance around $1.11 — above Street revenue expectations.
- Management highlights: AI agents and Cloudflare Workers driving more traffic and developer adoption.
- Cash/financials: >$4.1B in cash and marketable securities, improving free cash flow margins.
(Primary numbers come from Cloudflare’s February 10, 2026 press release and subsequent market coverage.) (cloudflare.net)
What changed — and why investors cheered
- Real beats, not just optics. Cloudflare’s Q4 revenue and non-GAAP EPS both beat Street estimates, and management pointed to one of its largest-ever ACV deals and accelerated new ACV growth. Those are hard, enterprise-level wins, not seasonal flukes. (cloudflare.net)
- AI activity = traffic multiplier. Cloudflare says AI-generated requests and “agentic” activity are meaningfully increasing the volume and complexity of traffic across its network. That trend boosts demand for edge compute (Workers), performance, and security services — Cloudflare’s core product set. Multiple analysts tied the beat to tailwinds from AI-driven traffic. (investors.com)
- Profitability is improving. GAAP still shows a loss from operations, but non-GAAP operating income and free cash flow expanded materially in Q4 — a signal that revenue growth is starting to translate into better margins and cash generation. (cloudflare.net)
Why the 2026 guide matters
Cloudflare’s guidance for 2026 (roughly $2.79B revenue) came in above consensus. That’s the cleanest proof management expects the AI-driven lift and large-account momentum to persist. Guidance beats reduce the uncertainty premium investors place on growth names and give analysts license to raise models — which often fuels short-term share-price pops.
But guidance also carried prudence on EPS: full-year adjusted EPS guidance was slightly below some expectations, implying Cloudflare is investing to capture growth even while improving margins. That mix — revenue optimism with measured margin assumptions — is typically viewed favorably by growth investors who want scale without runaway spending.
The investor dilemma: growth story vs. technical reality
-
Bull case: Cloudflare sits at the intersection of networking, security, and edge compute. If AI agents become permanent heavy users of the web, Cloudflare’s platform and its Workers developer ecosystem become sticky, high-margin revenue drivers. Large ACV deals and expanding RPO (remaining performance obligations) give the company predictable, durable revenue. (cloudflare.net)
-
Bear case: software multiples have been under pressure, and Cloudflare’s stock had seen institutional selling before this beat (technical indicators like Accumulation/Distribution were flagged as weak by market data providers). In plain terms: fundamentals are improving, but some investors may remain cautious until the company consistently delivers margin expansion and sustained higher growth rates. (investors.com)
-
The middle path: Treat the stock as an infrastructure growth play that merits patience. Short-term volatility is likely; the longer-term thesis hinges on AI traffic continuing to re-platform the Internet and Cloudflare converting that traffic into higher ARPU and enterprise traction.
What to watch next (near-term catalysts)
- Q1 2026 results and whether sequential revenue trends and margin expansion continue. Cloudflare guided Q1 revenue modestly above consensus; execution there will be telling. (investing.com)
- Growth of Cloudflare Workers and developer adoption metrics — these are leading indicators for future revenue per developer and platform monetization. (cloudflare.net)
- Deals and ACV cadence: will large deals keep accelerating, or was the big Q4 ACV a one-off? Large-contract momentum is central to the enterprise story. (cloudflare.net)
- Broader software multiple compression or expansion — macro moves in tech stocks will still sway Cloudflare’s share price regardless of company-level execution.
A few strategic takeaways for investors and builders
- Infrastructure is the quiet winner when usage patterns shift. When users (or agents) change how they interact with the web, companies that own reliable, global pipes and flexible edge compute win.
- Developer platforms scale differently. Success in developer adoption (Workers, SDKs, APIs) can create durable revenue streams if monetized thoughtfully.
- Cash and profitability matter even for growth names. Cloudflare’s >$4B cash cushion and improving free cash flow give it optionality to invest in product, sales, or tuck-in M&A while weathering market cycles. (cloudflare.net)
My take
Cloudflare’s Q4 and 2026 guide are a meaningful validation of the “Agentic Internet” thesis management has been selling: agents and AI workloads are real demand multipliers for edge and networking infrastructure. The numbers back the narrative — enterprise ACV growth, developer traction, and a rising cash flow profile are all positive. That said, investors should balance enthusiasm with discipline: stock moves from guidance beats can overshoot, and the share performance will still respond to broader sector sentiment and technical flows. If you believe AI agents materially re-platform web traffic, Cloudflare is a natural infrastructure play worth owning; if you’re skeptical about the durability of the lift or the multiple, use the recent rally as an opportunity to reassess position size rather than chase.
Sources
Related update: We recently published an article that expands on this topic: read the latest post.
AMD’s latest play: Ryzen 7 9850X3D lands with a price—and the market noticed
A single tweet, an MSRP, and a launch date: that was enough to nudge AMD shares higher last Friday. The Ryzen 7 9850X3D—an incremental, gaming-focused refresh—was given a January 29, 2026 release date and a $499 price tag, and investors reacted. But why does a modest mid-cycle CPU refresh move a multibillion-dollar chipmaker’s stock, and what should gamers and investors read into this?
Quick snapshot
- Product: AMD Ryzen 7 9850X3D
- Release date: January 29, 2026.
- MSRP: $499 (U.S.).
- Positioning: Higher-binned, 8-core/16-thread X3D chip with ~5.6 GHz boost and 96–104 MB effective cache (3D V-Cache).
- Market reaction: AMD stock rose on the announcement as the price and launch cleared uncertainty and reinforced AMD’s product cadence.
Why this mattered to traders
- Clarity reduces uncertainty. Markets dislike surprises—especially when rumors had floated higher retailer listings ($550–$600). AMD’s official $499 MSRP calmed fears of more aggressive pricing that could squeeze margins or signal weaker demand.
- Gaming chips still matter for perception. While AMD’s big revenue story in recent years has been data-center GPUs and AI-related products, consumer launches keep the brand momentum and signal healthy product execution across segments.
- It’s a signal about inventory and pricing strategy. A modest $20 uplift over the prior 9800X3D suggests AMD is managing positioning to avoid undercutting higher-tier SKUs while still offering a clearly tiered lineup for enthusiasts.
What the 9850X3D actually is
- Not a new architecture. This is a mid-cycle optimization—a “better-binned” 9800X3D—targeted at gamers who value per-core frequency and 3D V-Cache benefits for certain titles.
- Specs and expected gains. Same 8-core/16-thread configuration, a higher boost clock (~5.6 GHz), and AMD’s stacked 3D cache. AMD’s own messaging suggests modest single-digit percentage uplift compared to the 9800X3D—valuable for esports or frequency-sensitive workloads, less so for general productivity.
- Compatibility. Slots into AM5 motherboards (600- and 800-series); BIOS updates may be required on older boards.
The broader context
- CES 2026 timing. The 9850X3D revealed in the CES cycle helps AMD keep headlines during an event when investors and consumers expect product refreshes. That timing often amplifies market reaction.
- AI and data-center tailwinds remain the core story. Analysts and investors continue to tie AMD’s revenue narrative to server and AI demand—consumer CPU launches are important but secondary to the company’s enterprise trajectory.
- Pricing comparisons matter. With rumors of higher retailer markups earlier, the $499 MSRP positions AMD competitively against inflated early listings and helps set consumer expectations.
What this means for different audiences
- Gamers: If you want one of the fastest gaming CPUs and value incremental frame-rate gains in competitive titles, the 9850X3D looks appealing—assuming you can get it near MSRP. If you bought a 9800X3D recently, gains are small enough that regret would be mild.
- PC builders: Good option for high-end gaming builds, but weigh the CPU vs. GPU spend—gaming performance remains GPU-limited in many real-world scenarios.
- Investors: The stock bump reflects reduced uncertainty and a tidy product cadence. It’s a positive short-term signal but doesn’t change the long-term thesis that AMD’s data-center and GPU businesses drive most upside.
A few caveats
- Incremental upgrade: This is not a generational leap. Performance uplifts are modest and mostly frequency-driven.
- Retail availability vs. MSRP: Early retailer listings can still diverge from MSRP, especially in the first weeks. Buyers should watch actual retail pricing after launch.
- Market drivers remain diversified: Consumer product announcements help the narrative, but AMD’s valuation will continue to hinge on AI/data-center traction and margins in the server GPU market.
My take
The ripple in AMD’s stock after the Ryzen 7 9850X3D announcement is sensible: the market rewarded clarity. The $499 MSRP undercut some of the pessimism around pricing while confirming AMD continues to execute predictable product steps. For gamers and builders it’s a neat, targeted upgrade; for investors the move matters more as a sign of operational discipline than as a material earnings inflection. Keep watching AMD’s server and AI momentum—consumer chips are a headline, not the headline.
Sources
Related update: We recently published an article that expands on this topic: read the latest post.
A surprising pivot from Insmed: what the BiRCh results mean for brensocatib and the company’s strategy
The biotech world loves dramatic arcs: a promising molecule rises, investors cheer, and then — sometimes — the plot takes an unexpected turn. On December 17, 2025, Insmed released topline results from the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP). The verdict was blunt: the study did not meet its primary or secondary efficacy endpoints. Insmed immediately discontinued the CRSsNP program, while also announcing the acquisition of a Phase 2-ready monoclonal antibody, INS1148, to bolster its respiratory and inflammatory pipeline.
Let’s unpack what happened, why it matters, and where Insmed might reasonably go from here.
Quick summary of the news
- Date of announcement: December 17, 2025.
- Study: Phase 2b BiRCh — brensocatib versus placebo in CRSsNP, 24 weeks, ~288 patients across 104 sites.
- Result: Neither the 10 mg nor 40 mg dose met the primary endpoint (change in sinus Total Symptom Score) or secondary endpoints.
- Safety: No new safety signals; tolerability consistent with prior studies, including in the higher 40 mg arm.
- Immediate corporate action: Insmed discontinued the CRSsNP development program for brensocatib.
- Simultaneous strategic move: Acquisition of INS1148 (OpSCF), a monoclonal antibody intended for interstitial lung disease and moderate-to-severe asthma; Insmed plans Phase 2 development.
Why the BiRCh failure matters
- Brensocatib had momentum. The drug showed promising results in non-cystic fibrosis bronchiectasis (NCFB) and had become a central part of Insmed’s growth story. Expectations built around expanding brensocatib into other inflammatory and respiratory indications.
- CRSsNP is biologically complex with no reliable animal models. Insmed described the BiRCh trial as a proof-of-concept aimed at testing whether brensocatib’s DPP1 inhibition could translate into symptom relief. The neutral result gives a clear — if disappointing — answer.
- Financial and R&D implications. Discontinuing a development program reduces near-term R&D spend on that indication, but it also cuts potential long-term upside if CRSsNP had proven a meaningful market. The market reaction (sharp stock drop reported in related coverage) reflects lost optionality and investor re-pricing of future revenue scenarios.
- Scientific signal. The lack of efficacy despite adequate dosing (including the company’s highest dose tested) raises mechanistic questions about neutrophil serine protease inhibition in CRSsNP specifically. It also tempers optimism for other indications where the drug’s mechanism is less directly validated.
What the data showed (topline numbers)
- Primary endpoint (28-day average of daily sTSS at Week 24):
- Placebo LS mean: -2.44
- Brensocatib 10 mg LS mean: -2.21
- Brensocatib 40 mg LS mean: -2.33
- Safety: Treatment-emergent adverse events were similar between arms; no new safety concerns, and serious adverse event rates were low and comparable.
Those numbers show minimal separation from placebo on symptom improvement — the clinical signal simply wasn’t there.
The strategic pivot: INS1148 acquisition
- What Insmed bought: INS1148 is a monoclonal antibody (formerly OpSCF) that targets a specific isoform of Stem Cell Factor (SCF248). The proposed advantage is to block the inflammatory cascade downstream of c-Kit signaling while sparing homeostatic/tissue-healing pathways.
- Initial focus: Insmed plans Phase 2 programs in interstitial lung disease and moderate-to-severe asthma. This aligns with the company’s pulmonary focus and offers a new, complementary modality (mAb vs small-molecule DPP1 inhibitor).
- Why this matters: Acquiring a clinical-stage asset diversifies Insmed’s pipeline at a time when brensocatib’s expansion into CRSsNP is off the table. It signals the company is doubling down on respiratory/inflammatory areas while mitigating the impact of the BiRCh result.
The investor dilemma
- Near-term pain: Market volatility is expected after a late-2025 negative readout on an eagerly watched indication. Analysts and short-term traders will re-evaluate revenue forecasts and valuation multiples.
- Longer-term perspective: Insmed still has commercial momentum from brensocatib in bronchiectasis (marketed as Brinsupri in some territories), other ongoing studies (e.g., hidradenitis suppurativa CEDAR study), and now INS1148 to potentially broaden indications. For investors with a multi-year horizon, the company’s runway and portfolio execution matter more than a single failed indication.
- Risk-reward recalibration: The failure reduces optionality and likely moderates peak-sales estimates for brensocatib overall. But the absence of new safety signals and the company’s ability to redeploy capital toward a novel mAb program may keep upside for those who believe in Insmed’s broader strategy.
What this means for brensocatib’s other programs
- Hidradenitis suppurativa (HS) and other non-pulmonary indications may be scrutinized more closely. A lack of efficacy in CRSsNP doesn’t doom those programs, but it raises caution and increases the value of positive, indication-specific data.
- For bronchiectasis, prior strong late-stage results remain intact. Regulatory and commercial timelines for that indication are independent of the CRSsNP result, but market expectations may be tempered.
Takeaways for clinicians, patients, and industry watchers
- Clinicians and patients with CRSsNP: The BiRCh data suggest brensocatib will not become an option for CRSsNP. Patients should continue following evidence-based care and consult their physicians for approved therapies and management strategies.
- Industry watchers: This is a reminder that translating mechanism-based therapies into symptom relief in human disease is hard, especially in diseases lacking translational animal models. Creative acquisitions (like INS1148) are a common industry response to maintain pipeline momentum.
My take
Insmed’s BiRCh outcome is a textbook example of how clinical development reorders expectations. The result is disappointing, but not catastrophic: the company still has a commercially relevant product in bronchiectasis and a pipeline it can re-shape. Acquiring INS1148 is a pragmatic move — it signals an appetite to diversify modality risk and lean into respiratory immunology with a different mechanism.
Failures like this sting publicly because they are visible and immediate. But they can also sharpen corporate focus. If Insmed executes well on ongoing brensocatib programs and advances INS1148 thoughtfully into Phase 2, the company can emerge with a clearer, perhaps stronger strategic identity — albeit one that looks different than the path investors may have anticipated at the start of 2025.
Further reading
- Insmed press release: “Insmed Provides Clinical and Business Update” (December 17, 2025) — for the full topline text and company commentary.
- Reuters and other industry coverage — for market reaction and context around brensocatib’s prior successes in bronchiectasis.
Sources
Related update: We recently published an article that expands on this topic: read the latest post.